Evidence map›Paper›PMID 32600059›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2020

Development and verification of a personalized immune prognostic feature in breast cancer.

HongLei Wang, Li Wu, HongTao Wang

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

HongLei WangDepartment of Galactophore, The First Hospital of Lanzhou University, Lanzhou City, Gansu Province 730000, China.ORCID 0000-0002-5979-8331
Li WuDepartment of Galactophore, The First Hospital of Lanzhou University, Lanzhou City, Gansu Province 730000, China.
HongTao WangDepartment of General Surgery, The People's Hospital of Wuwei City, Wuwei City, Gansu Province 733000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

impact statementBreast cancer is among the highest prevalent malignant tumors worldwide with a low survival ratio. Immune-related genes have great potential as prognostic indicator in many types of tumors. Therefore, we have attempted to develop immune-related gene markers to enhance the prognosis of breast cancer. 17-IRGPs signature was constructed as a newly developed prognostic indicator to predict the survival of BC patients.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChildChild, PreschoolFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInfantInfant, NewbornMiddle AgedPrognosisBiomarkers, TumorBioinformaticsimmune genesIRGPsprognostic markersTCGA

Identifiers

PMID32600059
PMCPMC7437380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.